Sigma-Aldrich Enters Distribution Agreement with Stemgent for Regenerative Medicine

Sigma-Aldrich has entered into an exclusive worldwide distribution agreement with Stemgent, the latter’s portfolio of lentivirus-based delivery systems for the generation of induced Pluripotent Stem (iPS) cells.

The reprogramming technologies that are offered under the terms of the agreement involve proprietary viral vectors from Stemgent, lentivirus technology from Sigma-Aldrich and Dox Inducible expression from TET Systems. These technologies have been validated in Stemgent’s laboratories and are expected to allow researchers to efficiently reprogram mouse and human cells into iPS cells, enabling researchers to investigate and address the challenges facing the field of regenerative medicine.